Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation

Fangueiro, Joana F.; Andreani, Tatiana; Fernandes, Lisete; García, María L.; Egea, M.A.; Silva, Amélia M.; Souto, Eliana B.

doi:10.1016/j.colsurfb.2014.09.042

Cited by 89 publications

(36 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among cationic surfactants, CTAB (cetyltrimethylammonium bromide) and DDAB (dimethyldioctadecylammonium bromide) have been used in various industrial processes (e.g., as biocides and antiseptic agents [17]), and in the production of drug-loaded nanoparticles for various applications [4,[18][19][20][21][22][23]. While CTAB has a single chain and a single positive charged head-group, DDAB on the other hand is a double chain cationic lipid showing higher lipophilicity [24]. Because of these structural differences, CTAB and DDAB exhibit distinct capacity to interact and to disturb the plasmatic membrane of cells.…”

Section: Introductionmentioning

confidence: 99%

Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)

et al. 2019

Self Cite

View full text Add to dashboard Cite

The surface properties of nanoparticles have decisive influence on their interaction with biological barriers (i.e., living cells), being the concentration and type of surfactant factors to have into account. As a result of different molecular structure, charge, and degree of lipophilicity, different surfactants may interact differently with the cell membrane exhibiting different degrees of cytotoxicity. In this work, the cytotoxicity of two cationic solid lipid nanoparticles (SLNs), differing in the cationic lipids used as surfactants CTAB (cetyltrimethylammonium bromide) or DDAB (dimethyldioctadecylammonium bromide), referred as CTAB-SLNs and DDAB-SLNs, respectively, was assessed against five different human cell lines (Caco-2, HepG2, MCF-7, SV-80, and Y-79). Results showed that the cationic lipids used in SLN production highly influenced the cytotoxic profile of the particles, with CTAB-SLNs being highly cytotoxic even at low concentrations (IC50 < 10 µg/mL, expressed as CTAB amount). DDAB-SLNs produced much lower cytotoxicity, even at longer exposure time (IC50 from 284.06 ± 17.01 µg/mL (SV-80) to 869.88 ± 62.45 µg/mL (MCF-7), at 48 h). To the best of our knowledge, this is the first report that compares the cytotoxic profile of CTAB-SLNs and DDAB-SLNs based on the concentration and time of exposure, using different cell lines. In conclusion, the choice of the right surfactant for biological applications influences the biocompatibility of the nanoparticles. Regardless the type of drug delivery system, not only the cytotoxicity of the drug-loaded nanoparticles should be assessed, but also the blank (non-loaded) nanoparticles as their surface properties play a decisive role both in vitro and in vivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…This study suggested that the encapsulated EGCG in lipid nanoparticles inhibited oxidation and epimerization of drug. 19 Nevertheless, there are no studies on catechin and the PEG/ catechin nanocomplex in a dry eye mouse model. In this study, we hypothesized that PEG may increase the bioavailability of catechin, and thus the nanocomplex of catechin and PEG may have synergic and therapeutic effects for the treatment of dry eye disease to improve the anti-inflammatory effect of catechin.…”

mentioning

confidence: 99%

Therapeutic Efficacy of Nanocomplex of Poly(Ethylene Glycol) and Catechin for Dry Eye Disease in a Mouse Model

Lee

Shim

Kim

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Citation: Lee H, Shim W, Kim CE, Choi SY, Lee H, Yang J. Therapeutic efficacy of nanocomplex of poly(ethylene glycol) and catechin for dry eye disease in a mouse model. Invest Ophthalmol Vis Sci. 2017;58:168258: -169158: . DOI: 10.1167 PURPOSE. We investigated the possibility of the nanocomplex of poly(ethylene glycol) (PEG) and catechin as a new biomedical material to treat dry eye disease. METHODS. NOD.B10.H2b mice were exposed to an air draft and injected with scopolamine for 10 days. Ten days later, the mice were treated with normal saline (n ¼ 11), 1% catechin (n ¼ 11), 1% PEG (n ¼ 11), and 1% catechin/PEG nanocomplex solution mixture containing catechin and PEG at weight ratios of 1:1 (CP1, n ¼ 11), 1:5 (CP5, n ¼ 11), and 1:10 (CP10, n ¼ 11). All treatments were administered five times a day for 10 days. We estimated the effect of PEG/catechin nanocomplexes on inflammation, tear production, epithelium stabilization, and goblet cell density.RESULTS. Desiccation stress significantly decreased tear production and increased the corneal irregularity score. Furthermore, desiccation stress markedly increased the detached epithelium and decreased the numbers of conjunctival goblet cells. In addition, the expression of proinflammatory-related factors was markedly induced by desiccation stress in the lacrimal glands. However, the PEG/catechin nanocomplex effectively induced an increase in tear production, stabilization of the corneal epithelium, and an increase in conjunctival goblet cells and anti-inflammatory improvements in a PEG dose-dependent manner.CONCLUSIONS. In this study, we found that PEG may increase bioavailability of catechin. Therefore, the PEG/catechin nanocomplex can be used as a new biomedical material to treat dry eye disease through stabilization of the tear film and inhibition of inflammation.

show abstract

“…Similarly, both Camellia sinensis (green tea polyphenols) and Acacia cate-chu (Burma cutch) may be considered as flavan-3-ols enriched compounds. Cathecins such as epigallocathecin gallate have been proposed as new actives in nanoformulations for the management of diabetic retinopathy [123][124][125][126].…”

Section: Pterocarpus Marsupium and Other Epicatechin-containing Plantsmentioning

confidence: 99%

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

et al. 2019

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.

show abstract

Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation

Cited by 89 publications

References 59 publications

Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)

Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)

Therapeutic Efficacy of Nanocomplex of Poly(Ethylene Glycol) and Catechin for Dry Eye Disease in a Mouse Model

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

Contact Info

Product

Resources

About